SCHEMBL6202100

SCHEMBL6202100

Fc1cccc(-c2cocn2)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.56
NOTUM Q6P988 2/20 0.46
IDO1 P14902 2/20 0.46
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
KMO O15229 2/20 0.44
HPGDS O60760 1/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
MAP4K4 O95819 2/20 0.42
GRM5 P41594 2/20 0.41
F2RL1 P55085 1/20 0.41
PIM1 P11309 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
ESR2 Q92731 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14564377 0.79 SCN9A (0.62) SCN9AKMO
SCHEMBL4751198 0.78 HSD17B1 (0.58) SCN9A
SCHEMBL1354826 0.78 SCN9A (0.53) SCN9AKDM4EMEN1MAPTKMT2A
SCHEMBL17794305 0.78 SCN9A (0.53) SCN9AIDO1KDM4EMEN1MAPT
SCHEMBL10263248 0.78 SCN9A (0.53) SCN9ANOTUMIDO1KDM4EKMO
SCHEMBL30370470 0.78 SCN9A (0.53) SCN9ANOTUMIDO1KMOMAP4K4
SCHEMBL16159336 0.76 SCN9A (0.55) SCN9AESR2
SCHEMBL5836419 0.76 SCN9A (0.43) SCN9ANOTUMKDM4EMEN1KMT2A
SCHEMBL648786 0.76 SCN9A (0.53) SCN9AMEN1KMT2A
SCHEMBL8229086 0.76 SCN9A (0.46) SCN9ANOTUMKDM4EMAPTKMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501834-B1 TRIARYL-OXY-ARYL-SPIRO-PYRIMIDINE-2, 4, 6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PROD INC (US) 2005-09-07 EP disclosed
US-6916807-B2 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. (US) 2005-07-12 US disclosed
EP-1501834-A1 TRIARYL-OXY-ARYL-SPIRO-PYRIMIDINE-2, 4, 6-TRIONE METALLOPROTEINASE INHIBITORS Pfizer Products Inc. (US) 2005-02-02 EP disclosed
US-20030225056-A1 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. 2003-12-04 US disclosed
WO-2003091259-A1 TRIARYL-OXY-ARYL-SPIRO-PYRIMIDINE-2, 4, 6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225056-A1 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP9, TIMP3, MMP8 SCN9A 4510/4885NOTUM 3364/4885IDO1 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.